Ccnl1-flox 基因敲除小鼠

下单100%中奖,最高可得千元京东卡
复苏/繁育服务
产品名称

Ccnl1-flox 基因敲除小鼠

产品编号

S-CKO-12200

品系全称

C57BL/6JCya-Ccnl1em1flox/Cya

品系背景

C57BL/6JCya

品系编号

CKOCMP-56706-Ccnl1-B6J-VA

品系状态

使用本品系发表的文献需注明: Ccnl1-flox 基因敲除小鼠 mice (Strain S-CKO-12200) were purchased from Cyagen.
交付类型
周龄
性别
基因型
数量
cKO小鼠库模型

基本信息

基因研究概述

质控标准

基因
基因全称
cyclin L1
基因别称
2610030E23Rik,Ccnl,ania-6a
染色体号
Chr 3 (Mouse)
转录本 ID
NCBI: NM_019937 | Ensembl: ENSMUST00000029416
修饰方式
条件性基因敲除
靶向范围
Exon 4
敲除长度
~0.6 kb
品系说明
该品系是基于策略设计时的数据库信息制作而成,建议您在购买前查询最新的数据库和相关文献,以获取最准确的表型信息。
表型提示
Ccnl1,也称为Cyclin L1,是一种在细胞周期调控中发挥重要作用的蛋白质。Ccnl1主要参与细胞周期的G2-M期,与细胞增殖、分化和迁移等过程密切相关。Ccnl1的表达水平和活性受到多种因素的调控,包括基因突变、表观遗传修饰和信号通路等。

Ccnl1在多种癌症的发生和发展中发挥重要作用。研究发现,Ccnl1在头颈部鳞状细胞癌(HNSCCs)中过表达,且与临床病理参数无显著相关性[1]。Ccnl1在前列腺癌骨转移中通过N6-甲基腺苷(m6A)途径发挥重要作用,与骨转移和患者预后密切相关[2]。Ccnl1是SCF-FBXW7 E3连接酶的底物,其泛素化调控G2-M期进展,FBXW7突变导致Ccnl1积累缺陷,从而影响细胞有丝分裂时间[3]。Ccnl1的基因多态性与2型糖尿病视网膜病变的发生风险相关,提示其在糖尿病并发症中的作用[4]。Ccnl1在骨肉瘤中表达升高,且与阿霉素耐药性相关,通过PI3K/AKT-mTOR信号通路发挥重要作用[5]。Ccnl1与组织金属蛋白酶抑制剂-1(TIMP1)在乳腺癌细胞中存在微妙的平衡,共同影响乳腺癌的发生和发展[6]。Ccnl1是miR-5195-3p的直接靶基因,miR-5195-3p通过靶向Ccnl1抑制前列腺癌细胞的增殖和细胞周期进展[7]。Ccnl1与去氧胞苷激酶(DCK)共同参与胰腺癌的吉西他滨耐药性,通过激活ERK/AKT/STAT3生存通路发挥重要作用[8]。Ccnl1是miR-199b-5p的直接靶基因,miR-199b-5p通过靶向Ccnl1抑制Ewing's肉瘤细胞的增殖、侵袭和细胞周期进展[9]。Ccnl1在EB病毒阳性鼻咽癌中拷贝数增加,与较差的无病生存率相关[10]。

综上所述,Ccnl1在多种癌症的发生和发展中发挥重要作用,通过参与细胞周期调控、信号通路和基因表达等途径影响肿瘤的发生和发展。Ccnl1的研究有助于深入理解癌症的发病机制,为癌症的诊断和治疗提供新的思路和策略。

参考文献:
1. Muller, D, Millon, R, Théobald, S, du Manoir, S, Abecassis, J. . Cyclin L1 (CCNL1) gene alterations in human head and neck squamous cell carcinoma. In British journal of cancer, 94, 1041-4. doi:. https://pubmed.ncbi.nlm.nih.gov/16598186/
2. Wen, Simeng, Wei, Yulei, Zen, Chong, Niu, Yuanjie, Zhao, Yu. 2020. Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine. In Molecular cancer, 19, 171. doi:10.1186/s12943-020-01293-4. https://pubmed.ncbi.nlm.nih.gov/33308223/
3. O'Brien, Siobhan, Kelso, Susan, Steinhart, Zachary, Sicheri, Frank, Angers, Stephane. 2022. SCFFBXW7 regulates G2-M progression through control of CCNL1 ubiquitination. In EMBO reports, 23, e55044. doi:10.15252/embr.202255044. https://pubmed.ncbi.nlm.nih.gov/36278408/
4. Lin, Xiaohui, Wang, Jihong, Yun, Lixia, Zhang, Yihui, Ma, Xiaocheng. . Association between LEKR1-CCNL1 and IGSF21-KLHDC7A gene polymorphisms and diabetic retinopathy of type 2 diabetes mellitus in the Chinese Han population. In The journal of gene medicine, 18, 282-287. doi:10.1002/jgm.2926. https://pubmed.ncbi.nlm.nih.gov/27607899/
5. Zhang, Yanbin, Zhang, Tao, Chen, Long, Guo, Zijun, Jiang, Xiaobing. 2024. Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway. In Aging, 16, 11208-11223. doi:10.18632/aging.205972. https://pubmed.ncbi.nlm.nih.gov/39024509/
6. Peng, Li, Yanjiao, Ma, Ai-guo, Wang, Hongsheng, Ouyang, Xichen, Zhang. 2011. A fine balance between CCNL1 and TIMP1 contributes to the development of breast cancer cells. In Biochemical and biophysical research communications, 409, 344-9. doi:10.1016/j.bbrc.2011.05.021. https://pubmed.ncbi.nlm.nih.gov/21586274/
7. Zeng, Xing, Hu, Zhiquan, Shen, Yuanqing, Gan, Jiahua, Liu, Zheng. 2022. MiR-5195-3p functions as a tumor suppressor in prostate cancer via targeting CCNL1. In Cellular & molecular biology letters, 27, 25. doi:10.1186/s11658-022-00326-8. https://pubmed.ncbi.nlm.nih.gov/35260070/
8. Yang, Hai, Liu, Bin, Liu, Dongxue, Grützmann, Robert, Pilarsky, Christian. 2022. Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer. In Cancers, 14, . doi:10.3390/cancers14133152. https://pubmed.ncbi.nlm.nih.gov/35804923/
9. Li, Weihua, Li, Yuxia, Guo, Jiankuo, Zhang, Yongle, Wang, Xiao. 2015. Overexpression of miR‑199b‑5p inhibits Ewing's sarcoma cell lines by targeting CCNL1. In Molecular medicine reports, 12, 3359-3364. doi:10.3892/mmr.2015.3888. https://pubmed.ncbi.nlm.nih.gov/26043836/
10. Ooft, Marc Lucas, van Ipenburg, Jolique, van de Loo, Rob J M, Hardillo, J, Willems, Stefan Martin. 2018. Differences in cancer gene copy number alterations between Epstein-Barr virus-positive and Epstein-Barr virus-negative nasopharyngeal carcinoma. In Head & neck, 40, 1986-1998. doi:10.1002/hed.25195. https://pubmed.ncbi.nlm.nih.gov/29927011/